⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent central nervous system lymphoma

Every month we try and update this database with for recurrent central nervous system lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Acalabrutinib in CNSLNCT04906902
Central Nervous...
Refractory Cent...
Recurrent Centr...
Acalabrutinib
18 Years - Dana-Farber Cancer Institute
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: